A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study.

Gold, Julian; Marta, Monica; Meier, Ute C; Christensen, Tove; Miller, David; Altmann, Daniel; Holden, David; Bianchi, Lucia; Adiutori, Rocco; MacManus, David; +4 more... Yousry, Tarek; Schmierer, Klaus; Turner, Benjamin; Giovannoni, Gavin; (2018) A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study. Multiple sclerosis and related disorders, 24. pp. 123-128. ISSN 2211-0348 DOI: https://doi.org/10.1016/j.msard.2018.06.002

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/j.msard.2018.06.002

Abstract

Share

Download

Filename: A phase II baseline versus treatment_GREEN AAM.pdf

Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar